Dimensional Fund Advisors LP Sells 211,923 Shares of Hologic, Inc. $HOLX

Dimensional Fund Advisors LP reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,307,833 shares of the medical equipment provider’s stock after selling 211,923 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Hologic were worth $155,749,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its position in Hologic by 294.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after buying an additional 8,227,318 shares during the period. Invesco Ltd. boosted its position in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after acquiring an additional 3,505,828 shares during the period. Geode Capital Management LLC boosted its position in shares of Hologic by 1.7% in the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock valued at $378,209,000 after acquiring an additional 97,142 shares during the period. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 26.1% in the second quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after acquiring an additional 832,444 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Hologic by 2.2% during the second quarter. Bank of America Corp DE now owns 3,090,306 shares of the medical equipment provider’s stock worth $201,364,000 after acquiring an additional 66,453 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several analyst reports. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Finally, Morgan Stanley increased their price target on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Two research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Down 0.2%

Shares of Hologic stock opened at $75.59 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.75. The company has a market capitalization of $16.87 billion, a price-to-earnings ratio of 31.50, a PEG ratio of 2.25 and a beta of 0.73. The firm’s 50-day moving average price is $75.06 and its two-hundred day moving average price is $72.49.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. Hologic’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 earnings per share. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.